Almost one-third of the people suffering from epilepsy continue to have seizures in spite of using appropriate antiepileptics. Pharmacoresistance is defined as the failure to achieve seizure control with two or more anticonvulsant medications at appropriate daily dosage. Here, we discuss one such gentleman whose seizures had been intractable despite multiple antiepileptic drugs in maximum tolerable doses. Verapamil, a calcium channel blocker, was used for its P-glycoprotein inhibition properties to overcome the pharmacoresistance in this patient with satisfactory seizure control. There are a few studies with limited patients on the successful usage of verapamil in a patient with pharmacoresistant status epilepticus (SE). We intend to publish this case report to draw interest among the critical care physicians on pharmacoresistant SE, the different hypotheses that prevail, its causes and the available management strategies.
Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology 2001;57:2259-64.
Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman B, et al. Early development of intractable epilepsy in children: A prospective study. Neurology 2001;56:1445-52.
Camfield C, Camfield P, Gordon K, Smith B, Dooley J. Outcome of childhood epilepsy: A population-based study with a simple predictive scoring system for those treated with medication. J Pediatr 1993;122:861-8.
Go C, Snead OC 3rd. Pharmacologically intractable epilepsy in children: Diagnosis and preoperative evaluation. Neurosurg Focus 2008;25:E2.
Sillanpää M, Jalava M, Kaleva O, Shinnar S. Long-term prognosis of seizures with onset in childhood. N Engl J Med 1998;338:1715-22.
Beghi E. Efficacy and tolerability of the new antiepileptic drugs: Comparison of two recent guidelines. Lancet Neurol 2004;3:618-21.
Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
Schiller Y, Najjar Y. Quantifying the response to antiepileptic drugs: Effect of past treatment history. Neurology 2008;70:54-65.
Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. N Engl J Med 2011;365:919-26.
Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res 1996;23:139-48.
Jacoby A, Buck D, Baker G, McNamee P, Graham-Jones S, Chadwick D, et al. Uptake and costs of care for epilepsy: Findings from a U.K. regional study. Epilepsia 1998;39:776-86.
Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, et al. Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance. J Neurosci 2002;22:5833-9.
van Vliet EA, van Schaik R, Edelbroek PM, Redeker S, Aronica E, Wadman WJ, et al. Inhibition of the multidrug transporter P-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia 2006;47:672-80.
Liu X, Yang Z, Yang J, Yang H. Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 2007;53:657-63.
Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591-602.
Stępień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012;64:1011-9.
Nicita F, Spalice A, Raucci U, Iannetti P, Parisi P. The possible use of the L-type calcium channel antagonist verapamil in drug-resistant epilepsy. Expert Rev Neurother 2016;16:9-15.
Nicita F, Spalice A, Papetti L, Nikanorova M, Iannetti P, Parisi P, et al. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: A pilot study. Seizure 2014;23:36-40.
Narayanan J, Frech R, Walters S, Patel V, Frigerio R, Maraganore DM, et al. Low dose verapamil as an adjunct therapy for medically refractory epilepsy — An open label pilot study. Epilepsy Res 2016;126:197-200.